Phaseline

Companies › Elevara Medicines

Elevara Medicines: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Immunology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ELV001–Phase 2Active Rheumatoid ArthritisApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07409103ELV001Phase 2Active Rheumatoid ArthritisImmunologyApr 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Toll Biotech Co. Ltd. (Beijing) Ventus Therapeutics U.S. Navigator Medicines OrthoTrophix Resolve Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.